Biomarkers and short-term prognosis in COVID-19.

Autor: Peiró ÓM; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain., Carrasquer A; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain., Sánchez-Gimenez R; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain., Lal-Trehan N; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain., Del-Moral-Ronda V; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain., Bonet G; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain., Fort-Gallifa I; Clinical Laboratory, Catalan Institute of Health, Camp de Tarragona-Terres de l'Ebre, Tarragona, Spain., Picó-Plana E; Clinical Laboratory, Catalan Institute of Health, Camp de Tarragona-Terres de l'Ebre, Tarragona, Spain., Bastón-Paz N; Clinical Laboratory, Catalan Institute of Health, Camp de Tarragona-Terres de l'Ebre, Tarragona, Spain., Gutiérrez C; Clinical Laboratory, Catalan Institute of Health, Camp de Tarragona-Terres de l'Ebre, Tarragona, Spain., Bardaji A; Department of Cardiology, Joan XXIII University Hospital, Tarragona, Spain.; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.; Department of Medicine and Surgery, Rovira i Virgili University, Tarragona, Spain.
Jazyk: angličtina
Zdroj: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2021 Mar; Vol. 26 (2), pp. 119-126. Date of Electronic Publication: 2021 Jan 18.
DOI: 10.1080/1354750X.2021.1874052
Abstrakt: Purpose: The aim of our study was to analyse the short-term prognostic value of different biomarkers in patients with COVID-19.
Methods: We included patients admitted to emergency department with COVID-19 and available concentrations of cardiac troponin I (cTnI), D-dimer, C-reactive protein (CRP) and lactate dehydrogenase (LDH). Patients were classified for each biomarker into two groups (low vs. high concentrations) according to their best cut-off point, and 30-day all-cause death was evaluated.
Results: After multivariate adjustment, cTnI ≥21 ng/L, D-dimer ≥1112 ng/mL, CRP ≥10 mg/dL and LDH ≥334 U/L at admission were associated with an increased risk of 30-day all-cause death (hazard ratio (HR) 4.30; 95% CI 1.74-10.58; p  = 0.002; HR 3.35; 95% CI 1.58-7.13; p  = 0.002; HR 2.25; 95% CI 1.13-4.50; p  = 0.021; HR 2.00; 95% CI 1.04-3.84; p  = 0.039, respectively). The area under the curve for cTnI was 0.825 (95% CI 0.759-0.892) and, in comparison, was significantly better than CRP (0.685; 95% CI 0.600-0.770; p  = 0.009) and LDH (0.643; 95% CI 0.534-0.753; p  = 0.006) but non-significantly better than D-dimer (0.756; 95% CI 0.674-0.837; p  = 0.115).
Conclusions: In patients with COVID-19, increased concentrations of cTnI, D-dimer, CRP and LDH are associated with short-term mortality. Of these, cTnI provides better mortality risk prediction. However, differences with D-dimer were non-significant.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje